Clinical Risk Factors and Microbiological and Intestinal Characteristics of Carbapenemase-Producing Enterobacteriaceae Colonization and Subsequent Infection
- PMID: 36445086
- PMCID: PMC9769896
- DOI: 10.1128/spectrum.01906-21
Clinical Risk Factors and Microbiological and Intestinal Characteristics of Carbapenemase-Producing Enterobacteriaceae Colonization and Subsequent Infection
Abstract
Gastrointestinal colonization with carbapenem-resistant Enterobacteriaceae (CRE) is always a prerequisite for the development of translocated infections. Here, we sought to screen for fecal carriage of CRE and identify the risk factors for CRE colonization as well as subsequent translocated pneumonia in critically ill patients admitted to the intensive care unit (ICU) of a university hospital in China. We further focused on the intestinal flora composition and fecal metabolic profiles in CRE rectal colonization and translocated infection patients. Animal models of gastrointestinal colonization with a carbapenemase-producing Klebsiella pneumoniae (carbapenem-resistant K. pneumoniae [CRKP]) clinical isolate expressing green fluorescent protein (GFP) were established, and systemic infection was subsequently traced using an in vivo imaging system (IVIS). The intestinal barrier, inflammatory factors, and infiltrating immune cells were further investigated. In this study, we screened 54 patients hospitalized in the ICU with CRE rectal colonization, and 50% of the colonized patients developed CRE-associated pneumonia, in line with the significantly high mortality rate. Upon multivariate analysis, risk factors associated with subsequent pneumonia caused by CRE in patients with fecal colonization included enteral feeding and carbapenem exposure. Furthermore, CRKP colonization and translocated infection influenced the diversity and community composition of the intestinal microbiome. Downregulated propionate and butyrate probably play important and multiangle roles in regulating immune cell infiltration, inflammatory factor expression, and mucus and intestinal epithelial barrier integrity. Although the risk factors and intestinal biomarkers for subsequent infections among CRE-colonized patients were explored, further work is needed to elucidate the complicated mechanisms. IMPORTANCE Carbapenem-resistant Enterobacteriaceae have emerged as a major threat to modern medicine, and the spread of carbapenem-resistant Enterobacteriaceae is a clinical and public health problem. Gastrointestinal colonization by potential pathogens is always a prerequisite for the development of translocated infections, and there is a growing need to assess clinical risk factors and microbiological and intestinal characteristics to prevent the development of clinical infection by carbapenem-resistant Enterobacteriaceae.
Keywords: carbapenem-resistant Enterobacteriaceae; intestinal flora; metabolism; rectal colonization; risk factor.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
-
- Bes T, Nagano D, Martins R, Marchi AP, Perdigão-Neto L, Higashino H, Prado G, Guimaraes T, Levin AS, Costa S. 2021. Bloodstream infections caused by Klebsiella pneumoniae and Serratia marcescens isolates co-harboring NDM-1 and KPC-2. Ann Clin Microbiol Antimicrob 20:57. doi: 10.1186/s12941-021-00464-5. - DOI - PMC - PubMed
-
- Ham DC, Mahon G, Bhaurla SK, Horwich-Scholefield S, Klein L, Dotson N, Rasheed JK, McAllister G, Stanton RA, Karlsson M, Lonsway D, Huang JY, Brown AC, Walters MS. 2021. Gram-negative bacteria harboring multiple carbapenemase genes, United States, 2012-2019. Emerg Infect Dis 27:2475–2479. doi: 10.3201/eid2709.210456. - DOI - PMC - PubMed
-
- Meletiadis J, Paranos P, Georgiou PC, Vourli S, Antonopoulou S, Michelaki A, Vagiakou E, Pournaras S. 2021. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime and meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase producing clinical isolates. Int J Antimicrob Agents 58:106440. doi: 10.1016/j.ijantimicag.2021.106440. - DOI - PubMed
-
- Castanheira M, Doyle TB, Deshpande LM, Mendes RE, Sader HS. 2021. Activity of ceftazidime/avibactam, meropenem/vaborbactam, and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales (CRE) isolates from US hospitals. Int J Antimicrob Agents 58:106439. doi: 10.1016/j.ijantimicag.2021.106439. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
